Weekly Recap: Albumin revenue falls and Canadian collections restart

Weekly Recap: Albumin revenue falls and Canadian collections restart

Less than 1 min read

Grifols, S.A. Sponsored ADR Class B (BME:GRF) said albumin revenue fell 13.2% in the third quarter and 13.9% in the first nine months at constant currency. It reported €208 million in third-quarter free cash flow before M&A and does not expect an update on its potential U.S. Biopharma IPO review before 2027.

Previous Week Recap

- Albumin Revenue Falls, Slow Recovery: Grifols (GRF) said albumin revenue fell 13.2% in Q3 and 13.9% in the first nine months at constant currency. China’s recovery remains slow, with limited visibility on normalization.

2 sources - Canadian Plasma Centers Begin Restart: Grifols (GRF) paused plasma collection at all 17 Canadian centers in mid-August, then began a phased restart with regulators. Canadian sales continued, supplied by U.S.-sourced plasma.

MarketBeat - Nine-Month Free Cash Flow Grows: Grifols (GRF) reported €208 million in third-quarter 2026 free cash flow before M&A. Nine-month free cash flow reached €298 million, up €110 million year over year.

Estrategias de Inversión - U.S. Biopharma IPO Review Continues: Grifols, S.A. Sponsored ADR Class B (GRF) is co...